Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Completes Strategic Review to Strengthen the Organization and Drive Long-Term Growth
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the completion of a strategic review of its operations. As a result of this initiative, the Company will reduce its